Oncimmune Holdings PLC (LON:ONC) revealed that it has signed a ‘foothill contract’ with one of the world’s largest pharmaceuticals companies, which will evaluate the potential of Oncimmune’s technology to screen for lung cancer in at-risk patients.
This initial tie-up could be the “first step” towards a long-term partnership with the unnamed partner that would see the widespread availability of the EarlyCDT Lung test, investors were told.
The latest agreement is one of a series of deals inked in the last two months that showed the “full breadth” of the firm’s commercial offering, said chief executive Adam Hill.
“Our three-year strategy, announced in late 2018, centred on identifying and capitalising upon the wide range of opportunities presented by Oncimmune's proprietary autoantibody-based platform,” he explained in a statement.
“We firmly believe that the momentum we are building validates our strategy and underpins the commercial potential of our business.”